Rolapitant and Rosuvastatin Interaction
Drug interaction information between Rolapitant and Rosuvastatin.
Rolapitant and Rosuvastatin have a documented minor interaction in FDA labeling.
FDA drug labeling documents a minor-severity interaction between Rolapitant and Rosuvastatin. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.
How They Interact
Rolapitant blocks a protein that helps clear rosuvastatin from your body, which can lead to higher levels of the statin in your blood.
What To Do
Use the lowest dose of rosuvastatin that is effective for your condition.
FDA Label Information
Use the lowest effective dose of rosuvastatin (see prescribing information for additional information on recommended dosing).
Rolapitant Also Interacts With
- Pimozide major
- Thioridazine major
- Rifampin moderate
- Warfarin minor
- Methotrexate minor
Rosuvastatin Also Interacts With
- Sofosbuvir/Velpatasvir major
- Glecaprevir/Pibrentasvir major
- Febuxostat major
- Cyclosporine moderate
- Ledipasvir/Sofosbuvir moderate
Frequently Asked Questions
Can I take Rolapitant and Rosuvastatin together?
This is a minor interaction. Use the lowest dose of rosuvastatin that is effective for your condition.
How serious is the interaction between Rolapitant and Rosuvastatin?
This interaction is classified as "minor" severity by the FDA. Minor interactions are unlikely to cause significant problems but should still be mentioned to your healthcare provider.
Why do Rolapitant and Rosuvastatin interact?
Rolapitant blocks a protein that helps clear rosuvastatin from your body, which can lead to higher levels of the statin in your blood.
Understanding the Rolapitant and Rosuvastatin Interaction
FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Rolapitant belongs to the NK1 Receptor Antagonist (Antiemetic) class and Rosuvastatin belongs to the HMG-CoA Reductase Inhibitor (Statin) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Rolapitant blocks a protein that helps clear rosuvastatin from your body, which can lead to higher levels of the statin in your blood. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.
Context around a specific patient determines real-world impact. Rolapitant has 9 total documented interactions on file in this dataset, and Rosuvastatin has 21. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Use the lowest dose of rosuvastatin that is effective for your condition. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.
An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Rolapitant or Rosuvastatin based on a web page, speak with your prescriber or pharmacist before making any change.
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.
Read our methodology - how this data is sourced, computed, and verified.